Electromagnetic Field in Alzheimer's Disease: A Literature Review of Recent Preclinical and Clinical Studies.
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the progressive loss of neurons leading to cognitive and memory decay. The main signs of AD include the irregular extracellular accumulation of amyloid-beta (Aβ) protein in the brain and the hyper-phosphorylation of tau protein inside neurons. Changes in Aβ expression or aggregation are considered key factors in the pathophysiology of sporadic and early-onset AD and correlate with the cognitive decline seen in patients with AD. Despite decades of research, current approaches in the treatment of AD are only symptomatic in nature and are not effective in slowing or reversing the course of the disease. Encouragingly, recent evidence revealed that exposure to electromagnetic fields (EMF) can delay the development of AD and improve memory. This review paper discusses findings from in vitro and in vivo studies that investigate the link between EMF and AD at the cellular and behavioural level, and highlights the potential benefits of EMF as an innovative approach for the treatment of AD.
AI evidence extraction
Main findings
The review summarizes recent preclinical (in vitro and in vivo) and clinical evidence suggesting that electromagnetic field (EMF) exposure can delay the development of Alzheimer's disease and improve memory. It highlights EMF as a potential innovative approach for AD treatment based on cellular and behavioural findings.
Outcomes measured
- Alzheimer's disease development/progression
- Memory/cognitive function
- Amyloid-beta (Aβ) expression/aggregation
- Tau hyperphosphorylation
- Cellular and behavioural outcomes (in vitro and in vivo)
Limitations
- No specific EMF parameters (frequency
- SAR
- duration
- source) are provided in the abstract.
- The abstract does not describe search strategy
- inclusion criteria
- or quality assessment methods.
- Specific clinical study designs
- populations
- and effect sizes are not reported in the abstract.
View raw extracted JSON
{
"study_type": "review",
"exposure": {
"band": null,
"source": null,
"frequency_mhz": null,
"sar_wkg": null,
"duration": null
},
"population": null,
"sample_size": null,
"outcomes": [
"Alzheimer's disease development/progression",
"Memory/cognitive function",
"Amyloid-beta (Aβ) expression/aggregation",
"Tau hyperphosphorylation",
"Cellular and behavioural outcomes (in vitro and in vivo)"
],
"main_findings": "The review summarizes recent preclinical (in vitro and in vivo) and clinical evidence suggesting that electromagnetic field (EMF) exposure can delay the development of Alzheimer's disease and improve memory. It highlights EMF as a potential innovative approach for AD treatment based on cellular and behavioural findings.",
"effect_direction": "benefit",
"limitations": [
"No specific EMF parameters (frequency, SAR, duration, source) are provided in the abstract.",
"The abstract does not describe search strategy, inclusion criteria, or quality assessment methods.",
"Specific clinical study designs, populations, and effect sizes are not reported in the abstract."
],
"evidence_strength": "insufficient",
"confidence": 0.66,
"peer_reviewed_likely": "yes",
"keywords": [
"Alzheimer's disease",
"electromagnetic fields",
"EMF exposure",
"amyloid-beta",
"tau phosphorylation",
"memory",
"cognition",
"in vitro",
"in vivo",
"treatment"
],
"suggested_hubs": []
}AI can be wrong. Always verify against the paper.
Comments
Log in to comment.
No comments yet.
NNEMF synthesis
Synthesis pending.